The overall purpose of this study is to determine whether the cholesterol-lowering drug
simvastatin is effective in the treatment of symptoms of schizophrenia. The primary
hypothesis is that patients with schizophrenia receiving add-on treatment with simvastatin
will improve clinically (as measured mainly by symptom severity) compared with patients
receiving placebo, and that this improvement will be accompanied by concomitant reduction in
peripheral inflammatory markers.
Phase:
N/A
Details
Lead Sponsor:
New York State Psychiatric Institute
Collaborators:
Merck Sharp & Dohme Corp. Sheba Medical Center Stanley Medical Research Institute